Structure-based drug design for diagnosis and treatment of neurological diseases
Join CM1103:
If you are a Medicinal Chemist or computational chemist interested in drug design for the monoamine receptors or transporters and might be interested in joining the Action, please contact the Chair:
Dr Rona R Ramsay
COST Action CM1103
Structure-based drug design for diagnosis and treatment of neurological diseases:
dissecting and modulating complex function in the monoaminergic systems of the brain
WEBSITE DEVELOPMENT WORK IN PROGRESS
Welcome to the project website for COST Action CM1103. All official information about the Action CM1103 can be found on the COST website.
The purpose of this site is to inform the scientific community about our work and activities.
We promote collaboration and co-operation in drug discovery for diagnosing and modulating the function of the monoamine system in the brain that underlies or accompanies so many neuropathologies.
This Action was approved by COST Committee of Senior Officials on 17/05/2011.
Entry into force: 22/06/2011
Start of Action: 28/11/2011
End of Action: 27/11/2015
Abstract
The therapy of neuropsychiatric disorders is limited by the high variability of symptoms and behavioural disturbances. Few drugs are available to address specific subsets of neurological/mental symptoms, and none to aid in diagnosis or to stop the progress of neurodegenerative disorders. Neurotransmitters such as dopamine and serotonin play a central role in the pathophysiology of major neuropsychiatric illnesses, such as anxiety and mood disorders, schizophrenia, autism-spectrum disorders, Parkinson's disease, epilepsy, and dementias. Neurotransmitter-binding proteins such as receptors, transporters and common metabolic enzymes are the starting points for development of tools to diagnose and drugs to treat specific clusters of symptoms. Structure-based drug design, synthetic chemistry and biological characterisation will inform the choice of lead compounds to treat select subsets of brain malfunction. This COST collaboration facilitates the cross-disciplinary interaction for discovery of promiscuous
Contact Details
Chair of the Action:
Dr Rona R Ramsay (UK)
Vice Chair of the Action:
Prof Laura Della Corte (IT)
STMS Coordinator:
Prof Laura Della Corte (IT)
DC Rapporteur
Prof Dieter SCHINZER (DE)
Science Office
(COST Office):
Dr Lucia Forzi
Administrative Officer (COST Office)
Ms Svetlana Voinova
Grant Holder:
University of St Andrews (UK)
Administrative Officer & Grant Manager:
Ms Ann LeFeuvre
Participating Countries
COST countries: DE, DK, ES, IE, IT, HR, MT, PT, RS, SE
Collaborating or non-COST: AU, US, IL